All the Drug Class Drugs
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly. The dose should be incr. to 3.0 mg dly. in increm. of 0.6 mg with at least one week interv. to improve GI tolerabil. If escal. to the next dose step is not tolerated for two consec. wks., consider discount. tmt. Dly. doses higher than 3.0 mg are not recomm.
As an adjun. a reduced-calorie diet and incr. phys. active. for weight manag. in adult pts. with an init. BMI of ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid. such as dysglycaemia (pre-diab. or type 2 diab. mell.), hypertens. or dyslipidaemia, and who have failed a prev. weight manag. intervent. Tmt. should be discount. after 12 wks. on the 3.0 mg/day dose if pts. have not lost at least 5% of their init. bdy. wt.
Human Glucagon-Like Peptide-1, Long Acting Insulin. Insulin Glargine 100 UN, Lixisenatide 50 mcg / 33 mcg. PREF. SYR. ( Sol. for inj.): 1×3 ml. Dosage must be ajust. individ. See lit. Indicated in comb. with metformin for the tmt. of adult. with type 2 diab. mell. to improve glycemic control when this has not been provided by metformin alone or metformin comb. with another oral glucose low. med. product or with basal insulin.